Lyophilized azithromycin formulation

• US 20080221048A1
• Filed: 03/27/2008
• Published: 09/11/2008
• Est. Priority Date: 03/17/2004
• Status: Abandoned Application

• Current Assignee: APP Pharmaceuticals LLC (Fresenius SE & Co. KGaA)
• Original Assignee: APP Pharmaceuticals LLC (Fresenius SE & Co. KGaA)
• Inventors: Kwok, K. Keith, Yang, Kang Yong, Woo, Byung Ho
• Application Number:
  US12/079,770
• Publication Number:
  US 20080221048A1
• Time in Patent Office: Days
• US Class Current: 514/29
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient.

Claims

1. A stable, sterile pharmaceutical formulation comprising lyophilized azithromycin, an acid and ethanol, wherein the ethanol is present in an amount from about 0.003% to about 3.0% by weight of the pharmaceutical formulation, and wherein said acid is selected from the group consisting of citric acid monohydrate, anhydrous citric acid, sodium citrate, hydrochloric acid, lactic acid, glycolic acid, acetic acid, phosphoric acid, and tartaric acid, and wherein said formulation further comprises a base selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, and zinc hydroxide.

2. The formulation of claim 1, wherein the lyophilized azithromycin is present in an amount of about 500 mg.

3. The formulation of claim 1, wherein the ethanol is present in an amount of about 0.05% by weight of the pharmaceutical formulation.

4. The formulation of claim 1, wherein the majority of the lyophilized azithromycin is present in the form of azithromycin citrate.

5. The formulation of claim 1, wherein the majority of the lyophilized azithromycin is present in the form of sodium azithromycin citrate.

6. The formulation of claim 1, contained within a sealed container.

7. A solution prepared by dissolving the formulation of claim 1 in an aqueous vehicle.

8. The solution of claim 7, wherein the azithromycin is present in the solution in an amount of about 100 mg/mL or less.

9. A dilute solution prepared by diluting the solution of claim 8 in an aqueous vehicle.

10. The dilute solution of claim 9, wherein the azithromycin is present in the dilute solution in an amount from about 0.5 mg/mL to about 5 mg/mL.

11. A liquid composition comprising an ethanolate of azithromycin, citric acid, and sodium hydroxide.

12. The composition of claim 11, wherein the azithromycin is present in the composition in an amount from about 10 mg/mL to about 500 mg/mL.

13. A method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin, an acid and ethanol, which method comprises preparing a composition comprising an ethanolate of azithromycin, and lyophilizing the composition, wherein said acid is selected from the group consisting of citric acid monohydrate, anhydrous citric acid, sodium citrate, hydrochloric acid, lactic acid, glycolic acid, acetic acid, phosphoric acid, and tartaric acid, and wherein said formulation further comprises a base selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, and zinc hydroxide.